Psyence Net Interest Income from 2010 to 2025

PBMWW Stock   0.02  0.0002  0.90%   
Psyence Biomedical Net Interest Income yearly trend continues to be fairly stable with very little volatility. Net Interest Income is likely to outpace its year average in 2025. Net Interest Income is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. View All Fundamentals
 
Net Interest Income  
First Reported
2010-12-31
Previous Quarter
-45.7 K
Current Value
-43.4 K
Quarterly Volatility
18.9 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Psyence Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Psyence Biomedical's main balance sheet or income statement drivers, such as Interest Income of 1.4 K, Selling General Administrative of 1.8 M or Selling And Marketing Expenses of 97.3 K, as well as many indicators such as Price To Sales Ratio of 0.0, Ptb Ratio of 0.0 or Days Sales Outstanding of 0.0. Psyence financial statements analysis is a perfect complement when working with Psyence Biomedical Valuation or Volatility modules.
  
Check out the analysis of Psyence Biomedical Correlation against competitors.

Latest Psyence Biomedical's Net Interest Income Growth Pattern

Below is the plot of the Net Interest Income of Psyence Biomedical Ltd over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Psyence Biomedical's Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Psyence Biomedical's overall financial position and show how it may be relating to other accounts over time.
Net Interest Income10 Years Trend
Slightly volatile
   Net Interest Income   
       Timeline  

Psyence Net Interest Income Regression Statistics

Arithmetic Mean(8,651)
Geometric Mean0.00
Coefficient Of Variation(218.59)
Mean Deviation14,252
Median0.00
Standard Deviation18,911
Sample Variance357.6M
Range52.4K
R-Value(0.66)
Mean Square Error214.7M
R-Squared0.44
Significance0.01
Slope(2,634)
Total Sum of Squares5.4B

Psyence Net Interest Income History

2025-43.4 K
2024-45.7 K
2023-50.8 K
2022 1554.0

About Psyence Biomedical Financial Statements

Psyence Biomedical investors use historical fundamental indicators, such as Psyence Biomedical's Net Interest Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Psyence Biomedical. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Interest Income-45.7 K-43.4 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Psyence Stock Analysis

When running Psyence Biomedical's price analysis, check to measure Psyence Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Psyence Biomedical is operating at the current time. Most of Psyence Biomedical's value examination focuses on studying past and present price action to predict the probability of Psyence Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Psyence Biomedical's price. Additionally, you may evaluate how the addition of Psyence Biomedical to your portfolios can decrease your overall portfolio volatility.